Early vs standard zoledronic acid treatments for prostate cancer metastatic to bone

Study Type:Therapy

OE Level Evidence:2

Journal Level of Evidence:N/A

Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

J Clin Oncol. 2014 Apr 10;32(11):1143-50. doi: 10.1200/JCO.2013.51.6500.

Contributing Authors: MR Smith S Halabi CJ Ryan A Hussain N Vogelzang W Stadler RJ Hauke JP Monk P Saylor N Bhoopalam F Saad B Sanford WK Kelly M Morris EJ Small

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

645 patients with castration-resistant prostate cancer and bone metastases were randomized to either early administration of zoledronic acid or standard administration of zoledronic acid initiated following progression to castration-sensitive disease. The purpose was to determine whether early treatment would reduce time to developing a skeletal-related event (SREs) compared to standard treatment....